News

AELIX is partner in Horizon 2020 project MISTRAL

AELIX Therapeutics participates in the EU Horizon 2020 project MISTRAL

By VR | March 10, 2020

AELIX Therapeutics is a partner in the international Consortium of the MISTRAL project, funded within the framework of European Union’s Horizon 2020 programme with a Grant Agreement number 847943.

The MISTRAL project “Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications, antimicrobial drug resistance, and unresponsiveness to therapeutic HIV-1 vaccination” is exploring the gut microbiota in relation to HIV-1, seeking microbiome biomarkers to support development of interventions that mitigate infection and enhance response to vaccines and therapies. In addition, the creation of a publicly accessible database will aid in patient screening and stratification. A cloud-based tool will also facilitate microbiome interpretation for research and clinical purposes.

The budget of this project is € 9,99M.

More info:

https://cordis.europa.eu/project/id/847943

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847943

Return to all News

General Information

Pursuant to Article 10 of Law 34/2002 of 11th July, governing Information Society Services and E-Commerce (LSSI-CE), we make the following information available to you:
AELIX Therapeutics SL is domiciled at c/Baldiri Reixac 4-8, 08028 Barcelona, SPAIN, with VAT No. B66655598 and registered in the Commercial Registry of Barcelona, Volume 45116, Folio No. 49, Page 477310, Entry 1.
On the website www.aelixtherapeutics.com there is a series of informative content on their activities regarding the development of a therapeutic HIV vaccine to be used in cure/eradication strategies.
Its main purpose is to provide the general public with information relating to the company.

Use of the Website

The conditions of access and use of this website are governed by current legislation and by the principle of good faith, the user committing to make proper use of the website. Any conduct that is contrary to law or third party rights or interests is not permitted.
Being a user of the website www.aelixtherapeutics.com involves acknowledging that you have read and accepted these conditions and what is established by applicable legal regulations in this area. if, for any reason, you do not agree with these conditions, stop using this website.
Any kind of notice and/or claim will only be valid by written notice and/or registered mail.

Privacy Policy

Pursuant to the provisions of the Regulation (UE) 2016/679 of the European Parliament and of the Council on the protection of natural persons with regard to the processing of personal data and the Statutory Law 15/1999 of 13th December governing Personal Data Protection (LOPD) provided that it does not contravene the Regulation (UE) 2016/679, the user is informed that any data it provides us with will be included in a file created and maintained under the responsibility of AELIX Therapeutics SL.
The confidentiality of your personal data will always be respected. The data will only be used for the purposes of managing the services offered, attending to any requests you make. Further information concerning the processing of your data will be sent to you for your consent before storing the data. We will not store or process your personal data without your explicit consent..
The data controller of the processing of the personal data that you send through our website is AELIX Therapeutics SL with address at c/Baldiri Reixac 4-8, 08028 Barcelona (Spain), email address dataprotection@aelixtherapeutics.com and phone number +34934031339. To exercise your rights of access, limitation, opposition, rectification, cancellation or to withdraw consent you should address the company either by email or post to the aforementioned addresses.

Liabilities

AELIX Therapeutics SL is not liable for information and content stored on forums, social media or any other means that enable third parties to publish content independently on the website of the provider.
Nevertheless, considering Art. 11 and 16 of the LSSI-CE, AELIX Therapeutics SL commits to removing or, if applicable, blocking any content that could affect or violate national or international legislation, third party rights or morality and public order.
Nor will the company be liable for any damage or harm caused due to faults or incorrect configurations of software installed in the computer of the Internet user. All liability for any technical incidents or faults caused when the user connects to the Internet is excluded. Likewise, the non-existence of interruptions or errors in accessing the website is not guaranteed.

Update and Modification of the Website

AELIX Therapeutics SL reserves the right to update, amend or delete the information contained on its website, as well as its configuration or presentation and this Terms of Use, at any time, without assuming any liability therefor.

Intellectual and Industrial Property

AELIX Therapeutics SL is the holder of all the rights to the software of the digital publication, as well as the industrial and intellectual property rights regarding any content that is included, with the exception of rights on public products and services that are not the property of this company.
No material published on this website may be reproduced, copied or published without the written consent of AELIX Therapeutics SL.
Any information received on the website, such as comments, suggestions or ideas, will be deemed freely assigned to AELIX Therapeutics SL Any information that CANNOT be used in this way must not be sent.

Governing Law and Jurisdiction

These general conditions are governed by Spanish legislation. For any litigation that could arise in relation to the website or the activity executed therein, the courts of Barcelona will be competent, the user expressly waiving any other jurisdiction he could have recourse to.